Sydnexis is a San Diego based clinical stage pharmaceutical company currently in the middle of a pivotal Phase 3 study, focused on the development of a novel proprietary formulation of low dose atropine for the treatment of myopia. Myopia is a growing public health challenge worldwide that’s expected to affect 5 billion people by the year 2050.
Employees: 11-50
Total raised: $45M
Founded date: 2014
Investors 4
| Date | Name | Website |
| - | Visionary ... | visionaryv... |
| - | RA Capital... | racap.com |
| 14.08.2021 | Longitude ... | longitudec... |
| - | Bluestem C... | bluestemca... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 10.08.2021 | Series B | $45M | Visionary ... |
Mentions in press and media 4
| Date | Title | Description |
| 19.01.2024 | Sydnexis Welcomes Erin Horn as Vice President, Head of Market Access | DEL MAR, CALIFORNIA, USA, January 19, 2024 /EINPresswire.com/ -- January 19, 2023 – Sydnexis, Inc. (www.sydnexis.com), a clinical stage biopharmaceutical company focused on the treatment of progressive myopia in children and minimizing the ... |
| 11.08.2021 | Sydnexis Raises $45M in Series B Funding | Sydnexis, a San Diego CA-based biopharmaceutical company, raised $45M in Series B funding. The round was led by Visionary Ventures, Blue Stem Capital, and SC Master Fund with participation from RA Capital Management, Longitude Capital and M... |
| 10.08.2021 | Sydnexis Closes $45M Series B Funding Round | SAN DIEGO, CA, Sydnexis today announced the completion of a $45 million Series B financing. >> Click here for more funding data on Sydnexis >> To export Sydnexis funding data to PDF and Excel, click here Sydnexis, a clini... |
| 10.08.2021 | Sydnexis Secures $45 Million Series B Financing Led by Visionary Ventures and Blue Stem Capital | Sydnexis, Inc., a clinical stage biopharmaceutical company with a proprietary formulation of low dose atropine for the treatment of progressive myopia, today announced the completion of a $45 million Series B financing led by Visionary Vent... |